To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Alpha-PET for Prostate Ca… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Alpha-PET for Prostate Cancer: Preclinical investigation using Tb-149-PSMA-617

Journal article
Authors C. A. Umbricht
U. Koster
Peter Bernhardt
N. Gracheva
K. Johnston
R. Schibli
N. P. van der Meulen
C. Muller
Published in Scientific Reports
Volume 9
Pages 10
ISSN 2045-2322
Publication year 2019
Published at Institute of Clinical Sciences, Department of Radiation Physics
Pages 10
Language en
Links dx.doi.org/10.1038/s41598-019-54150...
Keywords radionuclide therapy, radioligand therapy, membrane antigen, in-vivo, dosimetry estimate, long-term, inhibitors, Science & Technology - Other Topics
Subject categories Biomedical Laboratory Science/Technology

Abstract

In this study, it was aimed to investigate Tb-149-PSMA-617 for targeted a-therapy (TAT) using a mouse model of prostate-specific membrane antigen (PSMA)-expressing prostate cancer. Tb-149-PSMA-617 was prepared with >98% radiochemical purity (6 MBq/nmol) for the treatment of mice with PSMA-positive PC-3 PIP tumors. Tb-149-PSMA-617 was applied at 1 x 6 MBq (Day 0) or 2 x 3 MBq (Day 0 & Day 1 or Day 0 & Day 3) and the mice were monitored over time until they had reached a pre-defined endpoint which required euthanasia. The tumor growth was significantly delayed in mice of the treated groups as compared to untreated controls (p < 0.05). TAT was most effective in mice injected with 2 x 3 MBq (Day 0 & 1) resulting in a median lifetime of 36 days, whereas in untreated mice, the median lifetime was only 20 days. Due to the beta(+)-emission of Tb-149, tumor localization was feasible using PET/CT after injection of Tb-149-PSMA-617 (5 MBq). The PET images confirmed the selective accumulation of Tb-149-PSMA-617 in PC-3 PIP tumor xenografts. The unique characteristics of Tb-149 for TAT make this radionuclide of particular interest for future clinical translation, thereby, potentially enabling PET-based imaging to monitor the radioligand's tissue distribution.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?